The Retina Clinic London, Institute of Ophthalmology, University College London
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Birch, David
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
Canada, US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
NAC Attack, NCT05537220: Oral N-acetylcysteine for Retinitis Pigmentosa

Recruiting
3
438
Europe, Canada, US, RoW
N-acetylcysteine, Placebo
Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania
Retinitis Pigmentosa
12/28
12/28
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
OCU400-101, NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

Active, not recruiting
1/2
22
US
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose
Ocugen
Retinitis Pigmentosa, Leber Congenital Amaurosis
03/27
03/27
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Recruiting
N/A
1500
Europe, Canada, US, RoW
Jaeb Center for Health Research, Foundation Fighting Blindness
Inherited Retinal Degeneration, Retinitis Pigmentosa
12/28
12/28
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Recruiting
N/A
50
US, RoW
PYC Therapeutics
Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
12/26
04/27
Locke, Kirsten
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
Canada, US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
OCU400-101, NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

Active, not recruiting
1/2
22
US
OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose
Ocugen
Retinitis Pigmentosa, Leber Congenital Amaurosis
03/27
03/27

Download Options